IP Library Granted Patent US 7,109,165
Granted Patent B2
US 7,109,165 · App. 10/151,116 · Granted Sep 19, 2006

Conjugates and compositions for cellular delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,109,165
App. No.
10/151,116
Granted
Sep 19, 2006
Kind
B2
Abstract

This invention features conjugates, compositions, methods of synthesis, and applications thereof, including folate derived conjugates of nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids and antisense nucleic acid molecules.

Claims (76)

1. A compound having the formula II:

wherein each R 3 , R 4 , R 5 , R 6 and R 7 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, or a protecting group, each “n” is independently an integer from 0 to about 200, R 12 is a straight or branched chain alkyl, substituted alkyl, aryl, or substituted aryl, and R 2 is a phosphorus containing group, a nucleoside, a nucleotide, a small molecule, a nucleic acid, or a solid support comprising a linker.

2. The compound of claim 1 , wherein R 2 is a phosphorus containing group.

3. The compound of claim 1 , wherein R 2 is a nucleoside.

4. The compound of claim 1 , wherein R 2 is a nucleotide.

5. The compound of claim 1 , wherein R 2 is a small molecule.

6. The compound of claim 1 , wherein R 2 is a nucleic acid.

7. The compound of claim 1 , wherein R 2 is a solid support comprising a linker.

8. The compound of claim 3 , wherein said nucleoside is a nucleoside with anticancer activity.

9. The compound of claim 3 , wherein said nucleoside is a nucleoside with antiviral activity.

10. The compound of claim 3 , wherein said nucleoside is fludarabine.

11. The compound of claim 3 , wherein said nucleoside is lamivudine (3TC).

12. The compound of claim 3 , wherein said nucleoside is 5-fluro uridine.

13. The compound of claim 3 , wherein said nucleoside is AZT.

14. The compound of claim 3 , wherein said nucleoside is ara-adenosine or ara-adenosine monophosphate.

15. The compound of claim 3 , wherein said nucleoside is a dideoxy nucleoside analog.

16. The compound of claim 3 , wherein said nucleoside is carbodeoxyguanosine.

17. The compound of claim 3 , wherein said nucleoside is ribavirin.

18. The compound of claim 3 , wherein said nucleoside is fialuridine.

19. The compound of claim 3 , wherein said nucleoside is lobucavir.

20. The compound of claim 3 , wherein said nucleoside is a pyrophosphate nucleoside analog.

21. The compound of claim 3 , wherein said nucleoside is an acyclic nucleoside analog.

22. The compound of claim 3 , wherein said nucleoside is acyclovir.

23. The compound of claim 3 , wherein said nucleoside is gangciclovir.

24. The compound of claim 3 , wherein said nucleoside is penciclovir.

25. The compound of claim 3 , wherein said nucleoside is famciclovir.

26. The compound of claim 3 , wherein said nucleoside is an L-nucleoside analog.

27. The compound of claim 3 , wherein said nucleoside is FTC.

28. The compound of claim 3 , wherein said nucleoside is L-FMAU.

29. The compound of claim 3 , wherein said nucleoside is L-ddC or L-FddC.

30. The compound of claim 3 , wherein said nucleoside is L-d4C or L-Fd4C.

31. The compound of claim 3 , wherein said nucleoside is an L-dideoxypurine nucleoside analog.

32. The compound of claim 3 , wherein said nucleoside is cytallene.

33. The compound of claim 3 , wherein said nucleoside is bis-POM PMEA (GS-840).

34. The compound of claim 3 , wherein said nucleoside is BMS-200,475.

35. The compound of claim 1 , wherein R 4 is tert-butyl, Fm (fluorenyl-methoxy), or allyl.

36. The compound of claim 1 , wherein R 6 is TFA (trifluoracetyl).

37. The compound of claim 1 , wherein R 3 , R 5 and R 7 are hydrogen.

38. The compound of claim 1 , wherein R 7 is isobutyryl.

39. The compound of claim 1 , wherein R 7 is dimethylformamide.

40. The compound of claim 1 , wherein R 7 is hydrogen.

41. The compound of claim 1 , wherein R 12 is methyl.

42. The compound of claim 1 , wherein R 12 is ethyl.

43. The compound of claim 6 , wherein said nucleic acid is an enzymatic nucleic acid.

44. The compound of claim 43 , wherein said enzymatic nucleic acid is a hammerhead.

45. The compound of claim 43 , wherein said enzymatic nucleic acid is an Inozyme.

46. The compound of claim 43 , wherein said enzymatic nucleic acid is a DNAzyme.

47. The compound of claim 43 , wherein said enzymatic nucleic acid is a cleaver.

48. The compound of claim 43 , wherein said enzymatic nucleic acid is a Zinzyme.

49. The compound of claim 43 , wherein said enzymatic nucleic acid is an Amberzyme.

50. The compound of claim 43 , wherein said enzymatic nucleic acid is an allozyme.

51. The compound of claim 6 , wherein said nucleic acid is an antisense nucleic acid.

52. The compound of claim 6 , wherein said nucleic acid is a 2-5A nucleic acid chimera.

53. The compound of claim 6 , wherein said nucleic acid is a decoy nucleic acid.

54. The compound of claim 4 , wherein said nucleotide is a nucleotide with anticancer activity.

55. The compound of claim 4 , wherein said nucleotide is a nucleotide with antiviral activity.

56. The compound of claim 7 , wherein said solid support comprising a linker of Formula XVII:

wherein SS is a solid support, and each “n” is independently an integer from 1 to 200.

57. The compound of claim 56 , wherein said solid support is controlled pore glass (CPG).

58. The compound of claim 56 , wherein said solid support is polystyrene.

59. The compound of claim 7 , wherein said compound is used in the synthesis of a nucleic acid.

60. A pharmaceutical composition comprising the compound of claim 1 in a pharmaceutically acceptable carrier.

61. A kit for detecting the presence of a nucleic acid in a sample, comprising the compound of claim 6 .

62. A kit for detecting the presence of a target molecule in a sample, comprising the compound of claim 6 .

63. A kit for detecting the presence of a nucleic acid in a cancer cell, comprising the compound of any of claim 50 .

64. A kit for detecting the presence of a nucleic acid in a virus infected cell, comprising the compound of claim 50 .

65. The compound of claim 1 , wherein said compound contains a modified phosphate.

66. The compound of claim 1 , wherein said phosphorus containing group is a phosphoramidite, phosphodiester, phosphoramidate, phosphorothioate, phosphorodithioate, alkylphosphonate, arylphosphonate, monophosphate, diphosphate, triphosphate, or pyrophosphate.

67. The compound of claim 3 , wherein said nucleoside is carbovir or abacavir.

68. The compound of claim 1 , wherein R 12 is an alkylhydroxyl.

69. The compound of claim 68 , wherein said alkylhydroxyl is —(CH 2 ) n OH.

70. The compound of claim 69 , wherein said n is an integer from 1–10.

71. The kit of claim 61 , wherein said sample is from a cancer cell.

72. The kit of claim 61 , wherein said sample is from a virus infected cell.

73. The kit of claim 62 , wherein said sample is from a cancer cell.

74. The kit of claim 62 , wherein said sample is from a virus infected cell.

Assignments (1)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →